Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as INS115644 Ophthalmic Solution
INS115644 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Arm 1 |
| 2 | EXPERIMENTAL | Arm 2 |
| 3 | EXPERIMENTAL | Arm 3 |
| 4 | EXPERIMENTAL | Arm 4 |
| 5 | EXPERIMENTAL | Arm 5 |
| Name | Type | Description |
|---|---|---|
| INS115644 Ophthalmic Solution | DRUG | One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days |
| Placebo | DRUG | One drop of placebo in each eye every 12 hours for three days |
Inclusion Criteria: * Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma * Have best corrected visual acuity in both eyes of at least +0.5 or better * Have normal endothelial cell counts and morphology Exclusion Criteria: * Are diagnosed with closed angle glauc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
| Glaukos Corp | GKOS | 2 | - | Travoprost |
INS115644 is an investigational small molecule developed by Merck & Company, Inc. (MRK) as an ophthalmic solution. It is being studied for ocular hypertension, a condition of elevated pressure inside the eye. INS115644 is in Phase 1 clinical development and is not approved for any use.
INS115644 is being evaluated as an ophthalmic solution for lowering intraocular pressure in patients with ocular hypertension. Its Phase 1 trial also enrolled subjects with open angle glaucoma. INS115644 remains investigational and has not been approved for treating ocular hypertension or any other condition.
INS115644 is developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck is the sponsor of the clinical program evaluating the ophthalmic solution in patients with ocular hypertension and open angle glaucoma.
INS115644 is in Phase 1 clinical development. Its only recorded trial, NCT00443924, was a Phase 1 study that has been completed. INS115644 is investigational and has not received FDA approval for ocular hypertension, open angle glaucoma, or any other indication.
INS115644 has been studied in one Phase 1 trial, NCT00443924, titled Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma. The trial enrolled 56 adults, was randomized, double blind, and placebo controlled, and it is now completed with no active trials ongoing.
Yes. INS115644 Ophthalmic Solution is the same asset as INS115644, referring to the eye drop formulation used in its clinical program. Both names describe the investigational small molecule that Merck & Company, Inc. is developing for ocular hypertension.